eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | acoustic neuroma |
| Comorbidity | C0085113|neurofibromatosis |
| Sentences | 17 |
| PubMedID- 22004800 | Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. |
| PubMedID- 20406973 | Patients with bilateral vestibular schwannomas associated with neurofibromatosis type 2 (nf2) experience significant morbidity such as complete hearing loss. |
| PubMedID- 24393766 | Two phase ii clinical trials (nct01207687, nct01125046) are assessing the effectiveness of bevacizumab in treating neurofibromatosis 2 patients with symptomatic vestibular schwannomas and recurrent or progressive meningiomas. |
| PubMedID- 20736812 | We sought to determine the activity of erlotinib for progressive vestibular schwannoma (vs) associated with neurofibromatosis 2 (nf2). |
| PubMedID- 25077310 | Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis type 2. |
| PubMedID- 23407292 | Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. |
| PubMedID- 22681725 | Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with neurofibromatosis type 2. |
| PubMedID- 26377980 | Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 25362541 | vestibular schwannoma in a patient with neurofibromatosis type 1: clinical report and literature review. |
| PubMedID- 24718755 | Audiovestibular characteristics of small cochleovestibular schwannomas in neurofibromatosis type 2. |
| PubMedID- 26287269 | Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2. |
| PubMedID- 22483820 | The focus is on management of sporadic, unilateral vestibular schwannomas, because patients with neurofibromatosis type 2 pose different management problems best discussed separately. |
| PubMedID- 20150363 | Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. |
| PubMedID- 21817944 | Objectives: to discuss our management strategy of vestibular schwannoma in patients with neurofibromatosis type 2 (nf2). |
| PubMedID- 24335931 | Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. |
| PubMedID- 22805104 | Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. |
| PubMedID- 26108240 | Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage. |
Page: 1